{"public_id":"cl_03591658db5e89280332789ee5e05f26","status":"active","superseded_by_public_id":null,"corpus_id":6793687,"text":"After 1 year, patients maintained with COP or OAP are projected to be free of disease at rates of 86% and 80%, respectively.","confidence":0.95,"paper":{"corpus_id":6793687,"title":"Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma","url":"https://sah.borca.ai/papers/6793687"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_1286c02c5043233107bafa3e974f68ee","name":"OAP","description":"A maintenance chemotherapy regimen containing arabinosyl cytosine, vincristine, and prednisone.","types":["chemotherapy regimen"],"url":"https://sah.borca.ai/concepts/co_1286c02c5043233107bafa3e974f68ee"},{"public_id":"co_387543277a219bdd33f3c584dcaaf019","name":"COP","description":"A maintenance chemotherapy regimen containing cyclophosphamide, vincristine, and prednisone.","types":["chemotherapy regimen"],"url":"https://sah.borca.ai/concepts/co_387543277a219bdd33f3c584dcaaf019"},{"public_id":"co_91f28a81d5112592744026522d116636","name":"free of disease","description":"A disease-free status projected at one year after maintenance therapy.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_91f28a81d5112592744026522d116636"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_03591658db5e89280332789ee5e05f26"}